Why AI Drug Discovery Is Entering Its Evidence Phase

AI drug discovery has spent the last few years in an awkward place between promise and proof. The pitch was irresistible: feed huge biological datasets into machine learning systems, identify better targets faster, design molecules in months instead of years, and cut some of the staggering cost of bringing a new therapy to market. What the sector lacked was not ambition, but evidence. That is why 2026 looks different. The conversation is shifting from “AI might transform pharma” to a harder question: where is the clinical signal?

Why the mood has changed

The biggest change is that the industry finally has enough real-world progress to judge AI drug discovery on something more meaningful than demo slides and discovery timelines. In the early wave, AI platforms were judged mostly on how quickly they could move from target identification to a preclinical candidate. That mattered, but it never answered the central question. A faster starting point is useful only if the compounds still hold up in the clinic.

That is where recent reporting around companies such as Insilico Medicine has become important. Its idiopathic pulmonary fibrosis candidate, rentosertib, has been closely watched because it represents one of the clearest end-to-end attempts to use AI throughout the discovery process and then test the result in people. Even cautious observers have treated those readouts as a milestone, not because one candidate proves the entire field, but because it begins to connect AI-assisted discovery with patient outcomes instead of lab efficiency alone.

From software story to biotech story

This matters because drug discovery is not a normal software problem. You cannot ship a beta to millions of users, patch bugs overnight, and declare success because engagement went up. Biology is noisy, disease mechanisms are messy, and most candidates fail for reasons that only become obvious deep into development. For AI companies, that means the real challenge was never just pattern matching. It was whether those models could help scientists make better biological bets.

That is also why the most serious players in the space have changed the tone of their own claims. Instead of saying AI replaces medicinal chemistry or eliminates clinical risk, they increasingly frame it as a way to improve hit identification, narrow the search space, rank candidates, surface hidden relationships in omics data, and make trial design more informed. In other words, AI is becoming part of the research stack, not magic above it.

The regulatory signal is just as important

Another reason the evidence phase matters is that regulators are no longer treating AI in drug development like a futuristic side note. The FDA has been building a more formal posture around AI credibility, model risk, and how algorithmic tools fit into submissions. That may sound bureaucratic, but it is actually healthy for the sector. If AI-discovered compounds are going to be taken seriously, the methods behind them need to be inspectable, auditable, and tied to reproducible scientific reasoning.

There is a similar shift happening elsewhere in the stack. DeepMind’s AlphaFold work helped reset expectations for what computational biology can achieve, but it also taught the market an important lesson: breakthrough tools create value when they slot into actual research workflows. Predicting structures is transformative. Turning that into validated drugs still requires experimental biology, chemistry, toxicology, manufacturing, and clinical execution. The winners will be the teams that connect those layers.

What investors got wrong, and what they are learning

The capital markets played a role in distorting expectations. For a while, “AI for drug discovery” was treated almost like a faster SaaS category with biotech upside attached. That framing encouraged investors to reward speed, platform breadth, and narrative ambition more than downstream proof. But biotech has a long memory. If a company cannot produce credible translational data, the valuation story eventually collapses into the same hard questions every therapeutic program faces.

In 2026, investors are getting more selective. They still like the category, but the bar is rising. They want to know whether a platform can generate differentiated assets, whether those assets show clinically meaningful effects, whether the company owns enough proprietary data to stay ahead, and whether the AI stack creates a defensible advantage rather than a glossy front end on outsourced science. That is a healthier market than hype alone.

Where AI is genuinely strongest today

The most believable case for AI in drug discovery is not that it removes uncertainty. It is that it helps scientists spend uncertainty more intelligently. Models can be useful in target prioritization, protein structure analysis, de novo design, ADMET prediction, biomarker discovery, patient stratification, and even in identifying which failed programs deserve a second look. These are not small gains. In a field where timelines are brutal and failure rates are normal, shaving off bad options early has enormous value.

There is also a growing case for AI in the less glamorous parts of development. Trial recruitment, protocol optimization, and signal detection across messy clinical data may ultimately matter as much as molecule generation. If the first generation of AI drug discovery was obsessed with designing compounds, the second may be judged on whether it improves the whole decision pipeline around them.

The real test is still ahead

Even so, the industry should resist declaring victory too early. One or two promising programs do not mean the model works everywhere. Biology is too heterogeneous for that. Some disease areas will be better suited to AI-assisted discovery than others, and some datasets will remain too sparse, biased, or fragmented to support reliable predictions. The hard work now is not selling the future. It is defining where AI consistently improves the odds.

That is what makes this moment interesting. The field is maturing out of the pitch deck era. Instead of asking whether AI can generate impressive molecules on paper, researchers, regulators, and investors are asking whether those molecules survive the unforgiving reality of clinical development. That is a much tougher standard. It is also the only one that matters. If 2026 produces more convincing readouts, AI drug discovery will not need evangelists nearly as much as it once did. The data will start speaking for itself.